Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in February-March

Keystone Symposia Epigenetic Mechanisms and Cancer TreatmentBio-Neuroscience17th Annual European Life Sciences CEO Forum BIO-Europe Spring 2024 MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE...
January 19, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
January 05, 2024 15:47 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th Sachs Annual Neuroscience Innovation Forum, on...
January 03, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in January

7th Sachs Annual Neuroscience Innovation Forum13rd Annual LifeSci Advisors Corporate Access EventBiotech Showcase-2024 42nd Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum 2024 ...
December 04, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.

To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN...
November 21, 2023 12:19 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million

Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous oneTo extend its cash runway and continue the ongoing clinical trials in CNS and oncology...
November 07, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)

Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD...
November 06, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in November

BIO-Europe 2023LSX Investival Showcase 2023Jefferies London Healthcare Conference 2023 MADRID, Spain and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015,...
October 27, 2023 12:12 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Positive aggregate safety data from vafidemstat's fully enrolled PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials,...
October 10, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

At the 36th European College of Neuropsychopharmacology congress (ECNP-2023) MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a...